miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways

Lung adenocarcinoma (LUAD) is one of the most common malignancies worldwide. Combination chemotherapy with cisplatin (CDDP) plus pemetrexed (PEM) remains the predominant therapeutic regimen; however, chemoresistance greatly limits its curative potential. Here, through CRISPR-Cas9 screening, we ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Guoshu, Liang, Jiaqi, Zhao, Mengnan, Zhang, Huan, Jin, Xing, Lu, Tao, Zheng, Yuansheng, Bian, Yunyi, Chen, Zhencong, Huang, Yiwei, Besskaya, Valeria, Zhan, Cheng, Wang, Qun, Tan, Lijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035384/
https://www.ncbi.nlm.nih.gov/pubmed/35505963
http://dx.doi.org/10.1016/j.omtn.2022.03.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035384/
https://www.ncbi.nlm.nih.gov/pubmed/35505963
http://dx.doi.org/10.1016/j.omtn.2022.03.020

Ejemplares similares